Allogeneic and Autologous Melanoma Vaccines: Where have we been and where are we going?
dc.contributor.author | Sondak, Vernon K. | |
dc.contributor.author | Sabel, Michael S. | |
dc.contributor.author | Mule', James J. | |
dc.date.accessioned | 2006-06-22T22:27:02Z | |
dc.date.available | 2006-06-22T22:27:02Z | |
dc.date.issued | 2006-04 | |
dc.identifier.citation | Clinical Cancer Research 2006;12(7 Suppl):2337s-2341s <http://hdl.handle.net/2027.42/39209> | en |
dc.identifier.uri | https://hdl.handle.net/2027.42/39209 | |
dc.description.abstract | The past three decades have seen substantial research on vaccines for the treatment of metastatic melanoma and the prevention of recurrence following resection. Despite their enormous promise, the actual results have been disappointing, with several high-profile vaccine clinical trials failing to showa benefit. Nonetheless, enthusiasm for melanoma vaccines remains and has increased with our expanding understanding of the immune response to tumor. Cellular vaccines can be divided into autologous, derived from the patient’s own tumor and allogeneic vaccines. Autologous vaccines have the advantage of containing all potentially relevant tumor-associated antigens for that particular patient. However, autologous vaccines are difficult to obtain from most patients with advanced disease and impossible to obtain from patients who present after resection of all clinically evident disease. No consensus exists for howt umors should be processed, preserved, modified, and delivered to serve as an effective vaccine. The amount of autologous tumor available is rarely enough to produce more than two or three vaccination doses, and the time between initial tumor harvest and ultimate availability of the vaccine may result in interval tumor progression that diminishes the likelihood of vaccine efficacy. All these drawbacks of autologous tumor vaccination limit its applicability and also limit the ability to test autologous vaccines in prospective trials. Allogeneic vaccines avoid many of these problems, but may not contain all of the tumor-associated antigens present on the patient’s own tumor. In particular, neoantigens created by mutations in the patient’s tumor would be unlikely to be represented in an allogeneic vaccine. Although allogeneic vaccines can be manufactured in sufficient quantities to allowl arge-scale trials, there remain significant limiting issues in the manufacture and standardization of the vaccine product. | en |
dc.format.extent | 84060 bytes | |
dc.format.mimetype | application/pdf | |
dc.language.iso | en_US | en |
dc.subject | Melanoma | en |
dc.subject | Vaccines | en |
dc.title | Allogeneic and Autologous Melanoma Vaccines: Where have we been and where are we going? | en |
dc.type | Article | en |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbsecondlevel | Surgery and Anesthesiology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | en |
dc.contributor.affiliationum | Surgical Oncology, Division of | en |
dc.contributor.affiliationumcampus | Ann Arbor | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/39209/1/Vaccines for melanoma- where are we going.pdf | en_US |
dc.owningcollname | Surgical Oncology Review Articles |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.